Eliyahu Sharon Kalif - 11 Jun 2026 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Reporting relationship: EVP, Chief Financial Officer
Issuer ticker: TEVA
Reported as of: 11 Jun 2026
Net transaction value: -$3,633,308
SEC form: 4
Accepted by SEC: 16 Jun 2026, 08:28:00 UTC
Prior SEC filing: 18 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Dov Bergwerk as attorney-in-fact for Eliyahu Sharon Kalif

Key filing fact

Eliyahu Sharon Kalif filed Form 4 for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on 16 Jun 2026.

Key facts

This page summarizes Eliyahu Sharon Kalif's Form 4 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 16 Jun 2026, 08:28.

Change

Previous filing in this sequence was filed on 18 May 2026.
Current net transaction value: -$3,633,308.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001798443 Primary reporting owner

Kalif Eliyahu Sharon

Relationship: EVP, Chief Financial Officer
Address: C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL
Signature: /s/ Dov Bergwerk as attorney-in-fact for Eliyahu Sharon Kalif
Signature date: 16 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TEVA transaction

Ordinary Shares

Sale

Transaction value: $3,633,308
Shares: -106,563
Change %: -62%
Price: $34.10
Shares after: 65,621
Date: 11 Jun 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Footnote F2

The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2025.

Footnote F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.985 to $34.25, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.